Biocartis Group NV (XBRU:BCART) ROCE % : -56.80% (As of Jun. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Biocartis Group NV ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Biocartis Group NV's annualized ROCE % for the quarter that ended in Jun. 2023 was -56.80%.

Biocartis Group NV ROCE % Historical Data

The historical data trend for Biocartis Group NV's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biocartis Group NV ROCE % Chart

Biocartis Group NV Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

ROCE %

Get a 7-Day Free Trial

-32.97

-31.33

-24.86

-43.05

-60.28

Biocartis Group NV Semi-Annual Data
	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
ROCE %	Get a 7-Day Free Trial															-40.46	-47.04	-51.22	-80.01	-56.80

Biocartis Group NV ROCE % Calculation

Biocartis Group NV's annualized ROCE % for the fiscal year that ended in Dec. 2022 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2022 )		(A: Dec. 2021 )		(A: Dec. 2022 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2022 )		(A: Dec. 2021 )		(A: Dec. 2022 )
	=	-54.434	/	( ( (142.48 - 33.705)	+	(114.277 - 42.449) )	/ 2 )
	=	-54.434	/	( (108.775	+	71.828)	/ 2 )
	=	-54.434	/	90.3015
	=	-60.28 %

Biocartis Group NV's ROCE % of for the quarter that ended in Jun. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Jun. 2023 )		(Q: Dec. 2022 )		(Q: Jun. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Jun. 2023 )		(Q: Dec. 2022 )		(Q: Jun. 2023 )
	=	-43.282	/	( ( (114.277 - 42.449)	+	(112.981 - 32.409) )	/ 2 )
	=	-43.282	/	( ( 71.828	+	80.572 )	/ 2 )
	=	-43.282	/	76.2
	=	-56.80 %

(1) Note: The EBIT data used here is two times the semi-annual (Jun. 2023) EBIT data.

Biocartis Group NV (XBRU:BCART) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Biocartis Group NV ROCE % Related Terms

Thank you for viewing the detailed overview of Biocartis Group NV's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Biocartis Group NV (XBRU:BCART) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Biocartis Group NV (XBRU:BCART) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Generaal de Wittelaan 11 B, Mechelen, BEL, 2800

Website

https://www.biocartis.com

Biocartis Group NV is a commercial-stage molecular diagnostics company. It provides diagnostic solutions aimed at improving clinical practice for patients, clinicians, payers, and the industry. The firm has developed an MDx Idylla molecular diagnostic system for oncology and infectious disease segments. Its products include EGFR mutation assay, BRAF mutation test, NRAS mutation test, respiratory panel, etc. The firm derives the majority of its revenues from product sales.

Biocartis Group NV (XBRU:BCART) Headlines

No Headlines